2. Search Result
Search Result
Results for "

Abemaciclib

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16297A
    Abemaciclib
    Maximum Cited Publications
    91 Publications Verification

    LY2835219

    		 CDK Cancer
    Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib
  • HY-126534A
    Abemaciclib metabolite M18 hydrochloride
    1 Publications Verification

    LSN3106729 hydrochloride

    		 Ligands for Target Protein for PROTAC CDK Cancer
    Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
    Abemaciclib metabolite M18 hydrochloride
  • HY-129336
    Abemaciclib metabolite M20
    4 Publications Verification

    LSN3106726

    		 CDK Cancer
    Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer .
    Abemaciclib metabolite M20
  • HY-16297AS
    Abemaciclib-d8

    LY2835219-d8

    		 CDK Cancer
    Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib-d8
  • HY-128669
    Abemaciclib metabolite M2
    1 Publications Verification

    LSN2839567

    		 CDK Drug Metabolite Cancer
    Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity .
    Abemaciclib metabolite M2
  • HY-129336S
    Abemaciclib metabolite M20-d8

    LSN3106726-d8

    		 CDK Cancer
    Abemaciclib metabolite M20-d8 is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].
    Abemaciclib metabolite M20-d8
  • HY-126534S
    Abemaciclib metabolite M18-d8

    LSN3106729-d8

    		 CDK Ligands for Target Protein for PROTAC Cancer
    Abemaciclib metabolite M18-d8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].
    Abemaciclib metabolite M18-d8
  • HY-16297AR
    Abemaciclib (Standard)

    		CDK Cancer
    Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib (Standard)
  • HY-16297R
    Abemaciclib methanesulfonate (Standard)

    		CDK Cancer
    Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .
    Abemaciclib methanesulfonate (Standard)
  • HY-126534
    Abemaciclib metabolite M18

    LSN3106729

    		 Ligands for Target Protein for PROTAC CDK Cancer
    Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
    Abemaciclib metabolite M18
  • HY-128669S
    Abemaciclib metabolite M2-d6

    LSN2839567-d6

    		 CDK Cancer
    Abemaciclib metabolite M2-d6 is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].
    Abemaciclib metabolite M2-d6
  • HY-16297
    Abemaciclib methanesulfonate
    Maximum Cited Publications
    91 Publications Verification

    LY2835219 methanesulfonate

    		 CDK Cancer
    Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .
    Abemaciclib methanesulfonate
  • HY-128669R
    Abemaciclib metabolite M2 (Standard)

    		CDK Drug Metabolite Cancer
    Abemaciclib metabolite M2 (Standard)
  • HY-162985
    JHD205

    		CDK Cancer
    JHD205 is a CDK4/6 inhibitor that induces apoptosis and DNA damage. JHD205 inhibits DNA repair by upregulating Caspase3 and p-H2AX. JHD205 has superior potency to Abemaciclib (HY-16297A) in a xenograft chick embryo breast cancer model. .
    JHD205
  • HY-168996
    LA-CB1

    		CDK Apoptosis Cancer
    LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC50 of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer .
    LA-CB1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: